Product Description
APG808, has been engineered to bind to and block IL-4Ra[EC1] to modulate dysregulated immune activity and to FcRn with high affinity to extend antibody half-life and potentially requiring less frequent dosing. IL-4Ra is a protein receptor that interacts with IL-13 and IL-4 as part of the body's natural inflammatory response. In COPD, this inflammatory signaling occurs more frequently and can trigger an exaggerated immune response. IL-4Ra is a well-established target for the treatment of COPD. (Sourced from: https://apogeetherapeutics.com/pipeline/)
Mechanisms of Action: IL4A Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Apogee Therapeutics
Company Location: Eastern America
Company Founding Year: 2022
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Apogee Therapeutics presented P1 Asthma results on 2025-05-12 for APG-808
- Clinical Outcomes Reported - Apogee Therapeutics announced they will present P1 Asthma results in 1H25 for APG-808
- Clinical Outcomes Reported - Apogee Therapeutics presented P1 Healthy Volunteers results on 2024-12-02 for APG-808
Highest Development Phases
Phase 1: Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12624000238572 |
ACTRN12624000238572 | P1 |
Completed |
Asthma |
2024-12-19 |
2026-02-15 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/12/2025 |
News Article |
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4RĪ± Antibody, in Patients with Mild-to-Moderate Asthma |
|
11/29/2024 |
News Article |
Apogee Therapeutics Announces Agenda for Virtual R&D Day |
|
12/02/2024 |
News Article |
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day |
|
05/23/2024 |
News Article |
Apogee Therapeutics to Participate in Upcoming June Investor Conferences |